Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
BEIJING YOUCARE KECHUANG PHARMACEUTICAL TECHNOLOGY CO., LTD. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct art unit. The case is being handled by 1 distinct examiner, Jaret James Crews. As the busiest examiner for the company, Jaret James Crews is responsible for the only pending action currently in the portfolio. This 1 matter represents the entirety of the current prosecution activity for the company within this technical sector.
With only 1 distinct examiner and 1 pending action, the prosecution is highly concentrated. There are no other pending matters to provide a baseline for comparison within the assigned art unit. Practitioners must focus their strategy entirely on the specific requirements and historical tendencies of Jaret James Crews. Because the company's current patent office presence is limited to this action, the outcome of this specific examination will be the primary factor in their near-term intellectual property results in the Biotechnology & Pharmaceuticals field. The lack of additional pending actions means that every development in this case carries significant weight for the company's portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CREWS, JARET JAMES | 1 | 44.7% | +70.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19336466 | GALNAC MONOMER COMPRISING RIBOSE RING OR DERIVATIVE STRUCTURE THEREOF AND USE THEREOF IN LIVER-TARGETED DELIVERY OF SMALL NUCLEIC ACID DRUGS | CREWS, JARET JAMES | — |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19336466 | GALNAC MONOMER COMPRISING RIBOSE RING OR DERIVATIVE STRUCTURE THEREOF AND USE THEREOF IN LIVER-TARGETED DELIVERY OF SMALL NUCLEIC ACID DRUGS | CREWS, JARET JAMES | 1691 | §103 | Final Rejection | — | Pending | Sep 22, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial